Press Release



Notice Concerning Dividends of Surplus

TOKYO, May 12, 2025 – ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886, Head Office: Minato-ku, Tokyo/ President, Representative Director: Takashi Yamaguchi) hereby announces that it has resolved, at a meeting of the Board of Directors held on May 12, 2025, to pay dividends of surplus with a record date of March 31, 2025.

This matter is scheduled to be officially decided upon approval at the Annual General Meeting of Shareholders of the Company to be held on June 24, 2025.

1. Details of dividend

	Determined amount	Most recent dividend forecast (Announced on February 3, 2025)	Actual results for the previous fiscal year
Record date	March 31, 2025	March 31, 2025	March 31, 2024
Dividend per share	¥30.00	¥25.00	¥20.00
Total amount of dividends	¥850 million	-	¥566 million
Effective date	June 25, 2025	-	June 26, 2024
Source of dividends	Retained earnings	_	Retained earnings

2. Reason

ASKA Pharmaceutical Holdings regards the return of profits to shareholders as one of the most important management issues. The Company's policy indicates a consolidated dividend payout benchmark ratio of 30% as performance-linked profit distribution. The Company will return profits to shareholders in an appropriate manner in line with business performance while maintaining stable profit distribution with a minimum annual dividend per share of 30 yen. With this, the annual dividend will be 55 yen per share, including an interim dividend of 25 yen, resulting in an increase of 15 yen per share compared to the previous fiscal year. Based on this, the consolidated dividend payout ratio will be 30.6%.

The dividend forecasts for FY2024 are as follows:

	Dividend per share (Yen)			
	Second quarter-end	Fiscal year-end	Total	
Previous dividend forecasts (Announced on February 3, 2025)	25.00	25.00	50.00	
Current dividend forecasts		30.00	55.00	
Actual results for the current fiscal year	25.00			
Actual results for the previous fiscal year (FY2023)	20.00	20.00	40.00	

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd. Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp